‘The FDA Will Be Looking For Avenues To Regulate Laboratory Developed Tests’

Decentralized, Multiple Site LDTs Could Be At Risk, Says McDermott Will & Emery Lawyer

The FDA's final LDT ruling was struck down in federal court last month. For now, diagnostic companies can commercialize under CLIA regulations or apply for FDA approval. McDermott and Tribun Health have shared insights on the risks, pros and cons of both regulatory routes.

LDTs

More from Conferences

More from US FDA